survivin-peptide double loaded dendritic cells
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2010 (NCT01456065)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- survivin-peptide double loaded dendritic cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06524063 | Phase 1 | Aug 1, 2024 | Beijing Tricision Biotherapeutics Inc |
| NCT01456065 | Phase 1 | Sep 1, 2010 | CellMed AG, Hospital Korneuburg |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Tricision Biotherapeutics Inc | Government | 1 | 1 | 1 | 2024 |
| CellMed AG | For profit | 1 | 1 | 1 | 2010 |
| Hospital Korneuburg | Academic/Hospital | 1 | 0 | 1 | 2010 |
3 organizations
Page 1 / 1